Sermorelin
Growth hormone axis · By Preptide Pro editorial team · Last updated
Sermorelin is a growth hormone axis peptide, and it has an FDA-approved product. A synthetic fragment (1-29) of growth-hormone-releasing hormone. It was previously FDA-approved as a diagnostic and pediatric product, and the brand was later discontinued.
Previously FDA-approved (discontinued)Chemistry (PubChem)
| PubChem CID | 16132413 |
|---|---|
| CAS number | 86168-78-7 |
| Molecular formula | C149H246N44O42S |
| Molecular weight | 3357.9 g/mol |
| Other names | Sermorelina, Sermoreline, Sermorelinum, CHEBI:9118, Groliberin, hGHRH(1-29)NH2, RefChem:182524, GHRH(1-29)NH2 |
Is Sermorelin FDA-approved?
| Brand | Application | Status | Sponsor |
|---|---|---|---|
| GEREF | NDA019863 | Discontinued | EMD SERONO |
| GEREF | NDA020443 | Discontinued | EMD SERONO INC |
How much research is there on Sermorelin?
PubMed lists 334 records for “sermorelin”, of which 29 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of growth hormone-releasing hormone. | Am J Physiol Heart Circ Physiol | 2026 Oct 1 |
| Growth hormone - releasing hormone antagonists protect endothelial corneal cells against lipopolysaccharides-induced inflammation. | Exp Eye Res | 2026 Oct |
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. | Sex Med Rev | 2026 Sep 30 |
| Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. | Sports Med | 2026 Aug |
| Anterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report. | Front Surg | 2026 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.